{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:20:56Z","timestamp":1786738856296,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Conventional treatments of atopic dermatitis have been inadequate, especially in patients with moderate-to-severe disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the past 5\u200ayears, four immunomodulators have been approved for the treatment of atopic dermatitis in children. These include dupilumab, ruxolitinib, upadacitinib, and abrocitinib. The review summarizes the pivotal phase 3 trials of these medications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The newer immunomodulators have transformed the treatment of atopic dermatitis, particularly in patients with moderate-to-severe disease. Dupilumab targets IL-4 and IL-13, which are the main causes of allergic inflammation, resulting in great efficacy and few side effects. Upadacitinib and abrocitinib are alternative systemic medications for adolescents who have failed or are unable to tolerate dupilumab. Ruxolitinib cream is the latest addition to the current topical therapy. It is indicated for children 12\u200ayears and older with mild-to-moderate atopic dermatitis. Further studies are needed to confirm its safety and efficacy for younger children and for patients with more severe disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001279","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T09:00:10Z","timestamp":1690794010000},"page":"671-679","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Recent advances in immunomodulators for atopic dermatitis"],"prefix":"10.1097","volume":"35","author":[{"given":"Hyun J.","family":"Yim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Jean","sequence":"additional","affiliation":[{"name":"Department of Allergy, Asthma, & Clinical Immunology, Kaiser Los Angeles Medical Center, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peck Y.","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles"},{"name":"Department of Pediatrics, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"417.e2","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ced.13853","article-title":"What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: epidemiology, aetiology and risk factors","volume":"44","author":"Lloyd-Lavery","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/DER.0000000000000582","article-title":"Insights from caregivers on the impact of pediatric atopic dermatitis on families: \u2018i\u2019m tired, overwhelmed, and feel like i\u2019m failing as a mother\u2019","volume":"31","author":"Capozza","year":"2020","journal-title":"Dermatitis"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"943640","DOI":"10.3389\/fimmu.2022.943640","article-title":"Atopic dermatitis: is innate or adaptive immunity in control? A clinical perspective","volume":"13","author":"Ong","year":"2022","journal-title":"Front Immunol"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjd.19751","article-title":"Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting","volume":"185","author":"Thomas","year":"2021","journal-title":"Br J Dermatol"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2147\/JAA.S293900","article-title":"Genetic\/environmental contributions and immune dysregulation in children with atopic dermatitis","volume":"15","author":"Chong","year":"2022","journal-title":"J Asthma Allergy"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12887-016-0607-9","article-title":"Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis","volume":"16","author":"Siegfried","year":"2016","journal-title":"BMC Pediatr"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"10.e2","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamadermatol.2022.0816","article-title":"The power of topical steroids","volume":"158","author":"Albrecht","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40264-015-0287-7","article-title":"Topical corticosteroid-induced skin atrophy: a comprehensive review","volume":"38","author":"Barnes","year":"2015","journal-title":"Drug Saf"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/0009922818825154","article-title":"Low risk of adrenal insufficiency after use of low- to moderate-potency topical corticosteroids for children with atopic dermatitis","volume":"58","author":"Davallow Ghajar","year":"2019","journal-title":"Clin Pediatr (Phila)"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"e046476","DOI":"10.1136\/bmjopen-2020-046476","article-title":"Safety of topical corticosteroids in atopic eczema: an umbrella review","volume":"11","author":"Axon","year":"2021","journal-title":"BMJ Open"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.18455","article-title":"Overcoming poor adherence is a major hurdle to managing atopic dermatitis","volume":"182","author":"Strowd","year":"2020","journal-title":"Br J Dermatol"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000086739","article-title":"Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis","volume":"211","author":"Hultsch","year":"2005","journal-title":"Dermatology"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"330","author":"Ashcroft","year":"2005","journal-title":"BMJ"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaip.2023.03.022","article-title":"A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis","volume":"11","author":"Pena","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","article-title":"Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis","volume":"156","author":"Asgari","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0091-6749(82)90008-2","article-title":"Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness","volume":"70","author":"Grewe","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20250730","first-page":"494.e6","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults [published correction appears in J Am Acad Dermatol. 2017 Apr;76(4):777]","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1)","volume":"21","author":"Schlessinger","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"411.e4","DOI":"10.1016\/j.jaad.2018.09.053","article-title":"Relative efficacy of systemic treatments for atopic dermatitis","volume":"80","author":"Seger","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2021.02.017","article-title":"Management of severe atopic dermatitis in pediatric patients","volume":"9","author":"Mancuso","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A Maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u200ayears old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial [published correction appears in J Am Acad Dermatol;84:230]","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6\u200amonths to younger than 6\u200ayears with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"158.e1","DOI":"10.1016\/j.jaad.2018.07.048","article-title":"Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"80","author":"Blauvelt","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-021-00607-6","article-title":"Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020","volume":"22","author":"Martinez-Cabriales","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial [published correction appears in JAMA Dermatol. 2021 Oct 1;157(10):1246]","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study [published correction appears in Lancet. 2023;401:194]","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br J Dermatol"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:01:14Z","timestamp":1753898474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001279","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]}}}